WTA
ALDX icon

Washington Trust Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Washington Trust Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,800
Closed -$14.5K – 686
2025
Q4 		$14.5K Hold
2,800
– – ﹤0.01% 463
2025
Q3 		$14.6K Sell
2,800
-1,000
-26% -$5.21K ﹤0.01% 478
2025
Q2 		$14.6K Hold
3,800
– – ﹤0.01% 433
2025
Q1 		$21.9K Hold
3,800
– – ﹤0.01% 390
2024
Q4 		$19K Hold
3,800
– – ﹤0.01% 411
2024
Q3 		$20.5K Hold
3,800
– – ﹤0.01% 406
2024
Q2 		$12.6K Hold
3,800
– – ﹤0.01% 442
2024
Q1 		$12.4K Hold
3,800
– – ﹤0.01% 452
2023
Q4 		$13.3K Buy
+3,800
New +$11.7K ﹤0.01% 435

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Washington Trust Advisors's ALDX Position: Q1 2026 in Review

Washington Trust Advisors sold out of Aldeyra Therapeutics (ALDX) in Q1 2026, closing a stake of 2,800 shares — an estimated $14.5K sold.

Washington Trust Advisors first reported a position in ALDX in Q4 2023 and held it in 9 quarters. The position peaked at $21.9K in Q1 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Washington Trust Advisors reported no remaining Aldeyra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Washington Trust Advisors sold 2,800 Aldeyra Therapeutics shares in Q1 2026, an estimated $14.5K.
  • Washington Trust Advisors first reported a position in Aldeyra Therapeutics in Q4 2023 and held it in 9 quarters.
  • Washington Trust Advisors's Aldeyra Therapeutics position peaked at $21.9K in Q1 2025.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Washington Trust Advisors's 13F filing for Q1 2026, filed 6 Apr 2026.